Astria Therapeutics price target raised to $20 from $13 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Astria Therapeutics to $20 from $13 and keeps a Buy rating on the shares. The Phase 1a healthy volunteer study for STAR-0215 offered a "significant profile building data for the antibody," Pantginis tells investors in a research note.